Vactosertib

▎药明康德内容团队编辑 本期看点 1. 治疗对CD19靶向CAR-T细胞疗法耐药的大B细胞淋巴瘤（LBCL）患者的CD22靶向CAR-T细胞疗法firi-cel公布积极1期临床试验数据，过半患者肿瘤完全消失。 2. 口服GLP-1和胰淀素的长效共激动剂amycretin在一项1期临床试验中使肥胖患者在用药12周后减重超过13.1%。 3. 治疗帕金森病的细胞疗法TED-A9在一项早期临床试验中使3名患者的运动能力获得显著改善。 药明康德内容团队整理 Firicabtagene autoleucel（firi-cel）：公布1期临床试验数据 CARGO Therapeutics公司宣布，《柳叶刀》杂志发表了斯坦福大学医学院进行的一项单中心1期临床研究的积极数据，该研究评估了CARGO公司的CD22靶向CAR-T细胞疗法firicabtagene autoleucel（firi-cel）治疗对CD19靶向CAR-T细胞疗法耐药的大B细胞淋巴瘤患者。这款CAR-T疗法是由患者自体T细胞经慢病毒载体（m971-BBZ）转导而制造出来的，目前CARGO Therapeutics拥有它的研发权利。 发布于《柳叶刀》的临床数据截至2023年5月22日，在中位随访时间23.3个月期间，所有接受治疗患者的总缓解率（ORR）和完全缓解（CR）率分别为68%和53%。CARGO在今年5月的欧洲血液学协会（EHA）大会上公布了该试验的更新数据。截至2024年2月1日，在中位随访31.4个月期间，所有接受治疗患者的ORR和CR率仍分别为68%和53%。其中，29例接受剂量水平1（DL1）治疗的患者在中位随访29.8个月时的中位总生存期（mOS）为25.7个月（95% CI：9.2-NE），预估的2年生存率为52%。对于达到CR的患者，其中位无进展生存期（PFS）、缓解持续时间和总生存期尚未达到。自2023年11月的最后一次数据截止以来，20名达到CR的患者中没有观察到新的复发。此外，在DL1中持续没有观察到3级或更高级别的细胞因子释放综合征（CRS）或免疫效应细胞相关神经毒性综合征（ICANS）的发生。新闻稿指出，美国FDA在检视试验初步数据后罕见地主动联系斯坦福医学中心，敦促其为该疗法申请突破性疗法认定（BTD）。 Amycretin：公布1期临床试验的新数据 诺和诺德（Novo Nordisk）公布了其口服GLP-1和胰淀素的长效共激动剂amycretin的详细1期临床试验结果。分析显示，试验12周时，接受最高剂量amycretin的受试者的体重降幅高达13.1%，且受试者的体重下降尚未达到平台期。根据此积极结果，诺和诺德将对amycretin进行进一步开发。 ▲Amycretin在1期试验中的减重效果（图片来源：参考资料[6]） 行业媒体Fierce Biotech在过去的报道中指出，已过STEP-1临床试验结果显示司美格鲁肽组患者在68周试验期间的体重降幅为14.9%。虽然不同临床试验之间的结果难以一同比较，但amycretin在1期试验早期结果中所展现的快速减重效果，体现了该药物的巨大潜力。目前诺和诺德正在计划进行更大规模和更长时间的研究以全面评估amycretin的疗效和安全性，其中，旨在评估该疗法皮下注射剂型的2期试验正在进行患者招募。 TED-A9：公布1/2a期临床试验数据 S.BIOMEDICS公司宣布了其细胞疗法TED-A9在治疗帕金森病的1/2期临床试验中的首批3名受试者的1年随访数据。TED-A9是一款通过对人类胚胎干细胞（hESC）进行小分子化合物处理而生成的高度纯化中脑多巴胺能祖细胞。 此次公布的3名接受低剂量TED-A9治疗的患者的数据表明了TED-A9的安全性和有效性。患者在细胞植入一年后进行的核磁共振成像（MRI）和CT扫描显示，细胞移植或手术均未出现相关的不良反应；多巴胺转运蛋白（DAT）脑成像（FP-CIT-PET）显示多巴胺转运蛋白水平增加，意味着多巴胺神经元可能已定植并与患者的帕金森病症状改善相关；客观测量运动功能的MDS-帕金森病统一评定量表（MDS-UPDRS）第III部分评估显示，平均得分从基线的61.7分下降到一年后治疗后的49.0分，改善了12.7分，显示患者的运动能力得到了显著的改善。 INT2104：获得澳大利亚人类研究伦理委员会批准启动1期临床试验 Interius BioTherapeutics公司宣布，已获得澳大利亚治疗用品管理局（TGA）的人类研究伦理委员会（HREC）批准和临床试验通知（CTN）许可，以进行其在研体内CAR-T疗法INT2104的临床1期试验，用以治疗B细胞恶性肿瘤。INT2104是一种在研慢病毒载体基因疗法，设计靶向CD7阳性的T细胞和NK细胞，并传递CAR转基因，以在体内生成效应CAR-T和CAR-NK细胞。这些CAR细胞靶向CD20阳性B细胞，用于治疗B细胞恶性肿瘤。与体外CAR-T疗法不同，INT2104是一种现货型的单剂量疗法，可通过静脉输注系统性给药，患者无需进行淋巴清除，治疗时不需要任何特殊设备或人员培训。 该疗法在临床前实验中展现出积极的抗肿瘤作用。在系统性淋巴瘤小鼠模型中，单次静脉输注广泛剂量范围的INT2104可实现肿瘤完全消除。在未进行化疗预处理的非人灵长类动物中，单次载体输注后观察到显著的B细胞耗竭且没有观察到药物毒性，其中一只动物的B细胞耗竭效果已持续超过6个月。Interius计划在2024年第四季度开始试验，并有望在2025年第一季度实现关键里程碑。根据行业媒体STAT报道，INT2104是首个进入人体临床试验的体内CAR-T疗法。 Rebonuputemcel：公布1/2期临床试验数据 DiscGenics公司宣布在International Journal of Spine Surgery杂志上发表了同种异体椎间盘祖细胞疗法（IDCT）rebonuputemcel治疗疼痛性腰椎退行性椎间盘疾病（DDD）的1/2期联合临床研究的结果。IDCT是一种独立的单次注射生物疗法，旨在阻止有症状的腰椎间盘退行性病变的进展，并使椎间盘由内而外再生。IDCT中的活性成分是从捐赠的成人椎间盘组织中提取的活的祖细胞群。这些细胞经过多步骤的富集和扩增，导致细胞显著增殖和表型变化。随后，这些椎间盘源细胞会与粘性透明质酸钠溶液和辅料混合，成为最终的现货型细胞疗法IDCT。IDCT需要冷冻保存，可在门诊环境下经皮注射到椎间盘中使用。IDCT已获得美国FDA的再生医学先进疗法（RMAT）认定和快速通道资格。 此次公布的结果显示，该研究达到了主要的安全性和有效性终点，单次椎间盘内注射高剂量IDCT可安全地增加椎间盘体积，并在腰椎间盘退行性病变患者注射后的2年内对患者的背痛、残疾和生活质量产生具有统计学意义和临床意义的改善。安全性方面，少数患者（18.3%）报告了严重不良事件，其中最高比例的报告来自安慰剂组。 AMT-130：公布1/2期临床试验的新数据 uniQure公司宣布其通过大脑直接注射的在研基因疗法AMT-130在治疗亨廷顿病（HD）的1/2期临床试验中获得积极中期结果。uniQure同时宣布AMT-130获得针对HD的首个RMAT认定。AMT-130是uniQure首个聚焦中枢神经系统的基因疗法，由AAV5载体携带专门沉默亨廷顿（HTT）基因表达的微RNA（microRNA），利用该公司专有的miQURE沉默技术，抑制突变亨廷顿蛋白的产生。在这项试验中，研究人员利用MRI成像引导，将基因疗法直接注射到大脑的壳核和尾状核中。 此次公布的结果显示，在24个月时，接受高剂量AMT-130治疗的HD患者的疾病进展减缓达80%，且其脑脊液（CSF）中的神经丝蛋白轻链（NfL）水平显著低于基线水平。此外，与基线相比，在24个月的随访中，接受高剂量AMT-130治疗患者的运动和认知功能测量结果几乎保持稳定。根据迄今为止的数据，AMT-130在两种剂量下均显示出良好的耐受性和安全性。没有报告新的与AMT-130相关的严重不良事件。 SKY-0515：公布1期临床试验数据 Skyhawk Therapeutics公司公布了SKY-0515在1期临床试验A部分和B部分中的积极结果。SKY-0515正被开发为亨廷顿氏病的潜在治疗药物。SKY-0515是Skyhawk公司通过其新型RNA剪接平台开发的在研小分子RNA剪接修饰剂，旨在减少HTT蛋白和PMS1蛋白。PMS1蛋白是体细胞CAG重复扩增和HD病理学的一个关键驱动因素。 ▲多剂量递增研究的结果（图片来源：参考资料[9]） 此次公布的结果显示，SKY-0515在健康受试者中显示出剂量依赖性的HTT mRNA降低，在多剂量递增研究中，最高剂量组的降低幅度为72%。SKY-0515在所有测试剂量下的耐受性均良好，鉴于这些积极的初步结果，该公司计划在2024年第三季度在患者组中进行剂量测试，并计划在明年年初启动2期研究。 STP122G：公布1期临床试验的中期数据 圣诺制药（Sirnaomics）宣布在研RNAi疗法STP122G用于抗凝治疗的1期临床试验的第二患者队列圆满完成，并公布了中期数据。STP122G为第三代靶向凝血因子XI的抗凝血药物，适用于先前治疗不能完全防止出血情况的凝血障碍患者。因子XI是一种主要由肝脏内的肝细胞所产生的酶，其在人体凝血过程中发挥着重要作用。作为一种基于圣诺制药的GalAhead mxRNA递送平台的候选RNAi疗法，STP122G以肝细胞为靶点，抑制因子XI的产生，具有长期疗效及较小的出血风险。 该临床试验的第二患者队列组由8名健康受试者组成。受试者通过皮下注射完成了50毫克剂量的注射，并接受了140天的随访。安全数据显示，没有发现剂量限制性毒性或严重不良事件，同时观察到了与剂量相关的靶点沉默活性。故此本次临床研究将推进至下一队列剂量组。 Danuglipron：公布1期临床试验数据 辉瑞（Pfizer）宣布，基于进行中1期试验的药代动力学研究结果，公司已选择推进每日一次改良释放剂型danuglipron的临床开发用于治疗肥胖患者。Danuglipron（PF-06882961）是一款小分子口服胰高血糖素样肽-1（GLP-1）受体激动剂，与大分子GLP-1类似物不同的是，它们可通过更为简便的口服方式使用，并且不受食物或者服用时间的限制。 此次公布的研究结果显示支持每日一次给药的药代动力学特征，其安全性与之前的danuglipron研究一致，在超过1400名研究受试者中未观察到肝酶升高。辉瑞计划在2024年下半年进行剂量优化研究，评估多种改良释放剂型的剂量，以为注册性试验提供信息。 RGT-61159：IND申请获得FDA许可 Rgenta Therapeutics公司宣布，其口服小分子RNA调节剂RGT-61159的IND申请获得FDA批准，可开展1a/1b期临床试验。RGT-61159旨在特异性调节转录因子MYB的RNA剪接，从而抑制致癌MYB蛋白的产生。RGT-61159有潜力抑制MYB蛋白过度表达的癌细胞的增殖或诱导细胞死亡。MYB是细胞增殖分化过程的主调节因子，它的异常表达已在多种人类癌症中得到证实，包括腺样囊性癌（ACC）、急性髓性白血病（AML）、T细胞急性淋巴细胞白血病（T-ALL）、结直肠癌（CRC）、小细胞肺癌（SCLC）和乳腺癌。RGT-61159正在开发用于治疗ACC、CRC和其他实体瘤，以及AML。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放 参考资料（可上下滑动查看） [1] uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease. Retrieved July 9, 2024, from https://www.globenewswire.com/news-release/2024/07/09/2910220/0/en/uniQure-Announces-Positive-Interim-Data-Update-Demonstrating-Slowing-of-Disease-Progression-in-Phase-I-II-Trials-of-AMT-130-for-Huntington-s-Disease.html [2] Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies. Retrieved July 9, 2024, from https://interiusbio.com/2024/07/interius-biotherapeutics-receives-hrec-approval-and-ctn-clearance-from-the-tga-to-commence-a-phase-1-clinical-trial-for-its-first-in-class-in-vivo-car-therapeutic-for-b-cell-malignancies-will-initiate/ [3] Sirnaomics宣布基于GalNAc RNAi疗法药物STP122G用于抗凝治疗的I期临床试验第二序列圆满完成并公布了中期数据. Retrieved July 8, 2024, from https://www.prnasia.com/story/453316-1.shtml [4] S.BIOMEDICS Dopamine Cell Therapy for Parkinson’s Disease with TED-A9 Shows Promising Results at 12 months in Phase I/IIa Clinical Trial. Retrieved July 9, 2024, from https://www.businesswire.com/news/home/20240709317387/en [5] CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet. Retrieved July 11, 2024, from https://investors.cargo-tx.com/news-releases/news-release-details/cargo-therapeutics-announces-phase-1-clinical-study-firi-cel-car [6] Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study. Retrieved July 8, 2024 from https://cattendee.abstractsonline.com/meeting/20620/presentation/846 [7] Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron. Retrieved July 11, 2024, from https://www.businesswire.com/news/home/20240710971928/en/Pfizer-Advances-Development-of-Once-Daily-Formulation-of-Oral-GLP-1-Receptor-Agonist-Danuglipron [8] DiscGenics Announces the International Journal of Spine Surgery Has Published Results from an FDA-Approved Study of an Allogeneic Disc Progenitor Cell Therapy for the Treatment of Adults with Lumbar Disc Degeneration. Retrieved July 11, 2024, from https://www.prnewswire.com/news-releases/discgenics-announces-the-international-journal-of-spine-surgery-has-published-results-from-an-fda-approved-study-of-an-allogeneic-disc-progenitor-cell-therapy-for-the-treatment-of-adults-with-lumbar-disc-degeneration-302192071.html [9] Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction. Retrieved July 12, 2024, from https://www.globenewswire.com/news-release/2024/07/10/2911098/0/en/Skyhawk-Therapeutics-Announces-Positive-Topline-Results-from-Parts-A-and-B-of-its-Phase-1-Clinical-Trial-of-SKY-0515-as-a-Treatment-for-Huntington-s-Disease-Reaching-72-Huntingtin-.html# [10] Spur Therapeutics Completes Enrollment in Phase 1/2 GALILEO-1 Trial of FLT201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial. Retrieved July 12, 2024, from https://www.globenewswire.com/news-release/2024/07/08/2909533/0/en/Spur-Therapeutics-Completes-Enrollment-in-Phase-1-2-GALILEO-1-Trial-of-FLT201-in-Gaucher-Disease-and-Selects-Dose-for-Planned-Phase-3-Trial.html [11] MedPacto's vactosertib shows positive results in US osteosarcoma pre-clinical trial. Retrieved July 12, 2024, from https://www.koreabiomed.com/news/articleView.html?idxno=24495 [12] Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors. Retrieved July 12, 2024, from https://www.prnewswire.com/news-releases/immorna-biotherapeutics-receives-us-fda-ind-clearance-to-conduct-phase-12-study-of-jcxh-211-iv-as-monotherapy-and-in-combination-with-checkpoint-inhibitor-in-patients-with-advanced-solid-tumors-302190627.html [13] Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201. Retrieved July 12, 2024, from https://www.globenewswire.com/news-release/2024/07/08/2909719/0/en/Immix-Biopharma-Doses-1st-Patient-in-U-S-AL-Amyloidosis-Trial-with-CAR-T-NXC-201.html [14] Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer. Retrieved July 12, 2024, from https://www.businesswire.com/news/home/20240707808760/en/ [15] Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis. Retrieved July 12, 2024, from https://www.globenewswire.com/news-release/2024/07/09/2910147/0/en/Abata-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-Clinical-Evaluation-of-ABA-101-in-Progressive-Multiple-Sclerosis.html [16] Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease. Retrieved July 12, 2024, from https://www.globenewswire.com/news-release/2024/07/09/2910198/0/en/Gain-Therapeutics-Announces-the-Completion-of-Dosing-in-the-Multiple-Ascending-Dose-MAD-of-the-Phase-1-Study-of-GT-02287-a-Novel-Small-Molecule-Therapy-for-Parkinson-s-Disease.html [17] Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr. Retrieved July 12, 2024, from https://www.globenewswire.com/news-release/2024/07/09/2910208/0/en/Monopar-Announces-First-Patient-Enrolled-in-First-in-Human-Phase-1-Trial-for-Its-Novel-Radiopharmaceutical-MNPR-101-Zr.html [18] Rgenta Therapeutics Announces FDA Clearance of IND Application for RGT-61159, an Oral Small Molecule RNA Modulator Designed to Halt Disease-Driver MYB Production in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC). Retrieved July 12, 2024, from https://www.prnewswire.com/news-releases/rgenta-therapeutics-announces-fda-clearance-of-ind-application-for-rgt-61159-an-oral-small-molecule-rna-modulator-designed-to-halt-disease-driver-myb-production-in-adenoid-cystic-carcinoma-acc-and-colorectal-cancer-crc-302192676.html [19] Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy. Retrieved July 12, 2024, from https://pipelinereview.com/tr1x-announces-first-patient-dosed-in-proof-of-concept-gvhd-trial-evaluating-trx103-a-first-in-class-type-1-treg-tr1-cell-therapy/ 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新

Each individual's risk of being diagnosed with primary bone sarcoma and their chances of recovery following diagnosis are influenced by a range of unique factors. In 2023, it is anticipated that 4K individuals of all ages in the United States will be diagnosed with primary bone sarcoma, including 2K males and 1.8K females. In 2020, approximately 400 cases were reported among those aged 15 to 19. LAS VEGAS, Nov. 28, 2023 /PRNewswire/ -- Bone sarcoma is a rare and aggressive form of cancer that originates in the bone tissue. It poses significant challenges during its treatment due to several factors. Firstly, its rarity often leads to delayed diagnosis, as symptoms can mimic other common conditions. Additionally, bone sarcoma typically affects children and young adults, making the emotional toll of the disease particularly challenging. Treatment often involves a combination of surgery, chemotherapy, and radiation therapy, which can be physically demanding and cause severe side effects. Moreover, because bone sarcoma tends to occur in the extremities, treatment may require complex and lengthy surgical procedures, potentially affecting mobility and quality of life. Furthermore, the risk of recurrence remains a constant concern, necessitating long-term monitoring and follow-up care. Despite these challenges, ongoing research and advancements in medical technology offer hope for improved outcomes and a better quality of life for those battling bone sarcoma. DelveInsight has recently released a series of epidemiology-based market reports focusing on benign bone sarcoma including Osteosarcoma Market Report, Ewing Sarcoma Market Report, and Chondrosarcoma Market Report. These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2019 to 2032 segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Additionally, the reports feature exhaustive analysis of prominent companies working with their emerging candidates in different stages of clinical development. Let's deep dive into the assessment of these bone sarcoma markets individually. Osteosarcoma Market Osteosarcoma is a rare bone tumor affecting having an annual incidence of 3.4 cases per million. It is the most prevalent form of bone cancer, primarily developed in the osteoblast cells of bones, with a predilection for long bones near the knee joint. However, it can also manifest in other locations, including the upper leg, lower leg, upper arm, and virtually any bone in the body, including those in the pelvis, shoulder, and skull. It has the potential to invade adjacent tissues, such as tendons and muscles, and can metastasize to distant organs or other bones via the bloodstream. As per DelveInsight analysts, the total incident population of osteosarcoma in the 7MM was ~2K in 2022. The estimates show the highest incident cases of osteosarcoma in the United States with ~1K cases in 2022, and it is expected to increase by 2032. Osteosarcoma is commonly treated through a combination of chemotherapy, surgery, and radiation therapy. Despite some recent developments, limited progress has been achieved since the late 1980s when chemotherapy was added to surgical treatment, leading to improved survival rates. Radiation therapy impacts both normal and cancerous cells, causing various effects. Chemotherapeutic drugs like cisplatin, doxorubicin, ifosfamide, and high-dose methotrexate with leucovorin calcium rescue (HDMTX) are widely used. Additionally, a few FDA-approved products, such as FUSILEV and KHAPZORY, are available for osteosarcoma treatment. As per DelveInsight analysis, the osteosarcoma market size is expected to increase at a significant CAGR by 2032. This growth would be fuelled by the increase in the patient pool and the expected entry of emerging therapies. Osteosarcoma Pipeline Therapies and Companies Lenvatinib: Eisai Naxitamab: Y-mAbs Therapeutics BAY80-6946: Bayer Vactosertib: MedPacto For a comprehensive view of the osteosarcoma market, check out the Osteosarcoma Market Assessment Ewing Sarcoma Market Ewing Sarcoma, a malignant tumor, typically initiates its growth within the bones, with a higher incidence among children and young adults, often manifesting during adolescence. Although it can originate in any bone, it predominantly affects the long bones, such as the thigh bone, shin bone, and upper arm bone. The pelvis bones are also frequently involved. In some cases, the tumor may originate in muscle and soft tissues. Common symptoms include bone stiffness, pain, swelling, or tenderness, along with tissue surrounding the affected bone. As per the assessment done by DelveInsight, the total incident cases of Ewing sarcoma in the 7MM comprised approximately 1.2K cases in 2022 and are projected to increase during the forecasted period. The management of Ewing sarcoma typically adopts a comprehensive approach, which may encompass surgery, chemotherapy, and radiation therapy. The National Comprehensive Cancer Network (NCCN) offers specific chemotherapy regimens for localized and metastatic Ewing sarcoma. For first-line treatment, NCCN suggests VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide), VAIA (vincristine, doxorubicin, ifosfamide, and dactinomycin), and VIDE (vincristine, ifosfamide, doxorubicin, and etoposide) for both initial presentations and as primary therapy for metastatic disease. In the second-line setting, NCCN recommends options like Cyclophosphamide and topotecan, Irinotecan + temozolomide ± Vincristine, Ifosfamide, carboplatin, etoposide, and Lurbinectedin. As per the latest Ewing Sarcoma Market Report, the total Ewing sarcoma market size in the 7MM is approximately USD 26 million in 2022 and is projected to increase during the forecast period (2023–2032). The expected introduction of upcoming therapies and the deepened integration of early patient screening, medication management in secondary care, and diverse clinical setups, ongoing research into optimal implementation approaches, and a surge in public awareness will ultimately pave the way for the advancement of efficient treatment choices. Ewing Sarcoma Pipeline Therapies and Companies SECLIDEMSTAT (SP-2577): Salarius Pharmaceuticals ZEPZELCA (LURBINECTEDIN): Jazz Pharmaceuticals and PharmaMar VERZENIO (ABEMACICLIB): Eli Lilly IBRANCE (PALBOCICLIB): Pfizer MECBOTAMAB VEDOTIN (BA3011): Bioatla IOPOFOSINE I 131 (CLR 131): Cellectar Biosciences TP-1287: Sumitomo Pharma Oncology NBRX-109: Inhibrx Explore in-depth for a comprehensive understanding of the Ewing Sarcoma Clinical Trials Chondrosarcoma Market Chondrosarcoma comprises a group of bone tumors originating from cells that overproduce cartilage. Among these tumors, conventional chondrosarcoma is the most frequent type and is generally associated with slow growth. Conversely, rarer subtypes like dedifferentiated chondrosarcoma, myxoid chondrosarcoma, clear cell chondrosarcoma, and mesenchymal chondrosarcoma tend to exhibit a more aggressive growth pattern and have the potential to spread to distant body parts. DelveInsight estimated that the total incident cases of chondrosarcoma in the 7MM comprised approximately 2K cases in 2022 and are projected to increase during the forecasted period. The management approach for chondrosarcoma is contingent upon factors like tumor type, grade, and location, with the grading system serving as the most reliable indicator of clinical prognosis. It is firmly established that surgical intervention remains the gold standard and sole effective treatment for chondrosarcoma, as alternative modalities such as radiotherapy and chemotherapy exhibit limited responsiveness and resistance. Surgical options encompass curettage, radical resection, and amputation, each necessitating comprehensive clinical judgment and contingent upon variables such as lesion size, location, and malignant characteristics. Anticipated advancements in upcoming therapies and increased integration of early patient screening and medication within secondary care and other clinical settings, along with ongoing research to determine the best implementation methods, are expected to contribute to the development of more effective treatment options. However, chondrosarcoma, being an orphan disease, presents challenges in conducting clinical trials. Limited outcome data for locally advanced or metastatic patients underscore the need for new treatment approaches. Phase I trials, due to their small number of chondrosarcoma patients at varying dose levels, make it difficult to draw definitive conclusions. Nevertheless, some Phase II trials have yielded promising results, warranting further investigation. Encouraging retrospective studies could help augment the currently limited data. Urgent efforts to boost research studies on this orphan disease are imperative. As per DelveInsight analysis, the total market size of chondrosarcoma in the 7MM is approximately USD 9 million in 2022 and is projected to increase at a massive CAGR of 24.8% due to increasing awareness of the disease and the launch of the emerging therapy. Chondrosarcoma Pipeline Therapies and Companies INBRX-109: Inhibrx To access a complete analysis of the chondrosarcoma market, visit Chondrosarcoma Market Assessment Trending Oncology Reports Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, among others. Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including GAbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Oncolytic Virus Cancer Therapies Market Oncolytic Virus Cancer Therapies Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key oncolytic virus cancer therapies companies, including Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, among others. Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Johnson & Johnson (Janssen), Pfizer, AbbVie and Roche (Genentech), Regeneron Pharmaceuticals, Bristol-Myers Squibb, Celgene, Roche (Genentech), Arcellx, Novartis, Regeneron Pharmaceuticals, BeiGene, CARsgen Therapeutics, Cartesian Therapeutics, C4 Therapeutics, Heidelberg Pharma, Bristol-Myers Squibb, RAPA Therapeutics, AbbVie (TeneoOne), Takeda, among others. Oncology Conference Coverage Services DelveInsight's Oncology Conference Coverage Services deliver a comprehensive examination of conference outcomes from a range of prominent events, such as ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, European CAR T-cell Meeting, and IASLC 2023. This in-depth analysis equips businesses with the insights they need for effective competitive intelligence and forecasting market trends, aiding in the development of future strategies. About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP